ArticleCancer chemotherapy and pharmacology2011

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.

Haruyasu Murakami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.